
AKBA Valuation
Akebia Therapeutics Inc
- Overview
- Forecast
- Valuation
- Earnings
AKBA Relative Valuation
AKBA's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, AKBA is overvalued; if below, it's undervalued.
Historical Valuation
Akebia Therapeutics Inc (AKBA) is now in the Overvalued zone, suggesting that its current forward PS ratio of 5.16 is considered Overvalued compared with the five-year average of -5.08. The fair price of Akebia Therapeutics Inc (AKBA) is between 0.90 to 2.22 according to relative valuation methord. Compared to the current price of 3.56 USD , Akebia Therapeutics Inc is Overvalued By 60.72%.
Relative Value
Fair Zone
0.90-2.22
Current Price:3.56
60.72%
Overvalued
Trailing
Forward
P/E
P/E
EV/EBITDA
EV/EBIT
P/S
P/OCF
P/FCF
1Y
3Y
5Y
Trailing
Forward
37.89
P/B
Median3y
-0.91
Median5y
0.61
-3.46
FCF Yield
Median3y
-45.41
Median5y
-56.40
Competitors Valuation Multiple
The average P/S ratio for AKBA's competitors is 3.58, providing a benchmark for relative valuation. Akebia Therapeutics Inc Corp (AKBA) exhibits a P/S ratio of 4.94, which is 37.93% above the industry average. Given its robust revenue growth of 75.84%, this premium appears sustainable.
P/S
P/E
EV/EBITDA
EV/EBIT
P/S
Revenue Growth
Market Cap
People Also Watch

LAES
Sealsq Corp
3.320
USD
-1.78%

EQV
EQV Ventures Acquisition Corp
10.450
USD
-0.29%

SIGA
SIGA Technologies Inc
7.140
USD
+1.13%

CENT
Central Garden & Pet Co
40.290
USD
+0.15%

PACB
Pacific Biosciences of California Inc
1.540
USD
0.00%

AAM
AA Mission Acquisition Corp
10.448
USD
-0.02%

MTLS
Materialise NV
5.325
USD
0.00%

MUX
McEwen Inc
11.360
USD
-1.22%

ANNX
Annexon Inc
2.510
USD
-1.57%

YORW
York Water Co
30.570
USD
-1.42%
FAQ

Is Akebia Therapeutics Inc (AKBA) currently overvalued or undervalued?
Akebia Therapeutics Inc (AKBA) is now in the Overvalued zone, suggesting that its current forward PS ratio of 5.16 is considered Overvalued compared with the five-year average of -5.08. The fair price of Akebia Therapeutics Inc (AKBA) is between 0.90 to 2.22 according to relative valuation methord. Compared to the current price of 3.56 USD , Akebia Therapeutics Inc is Overvalued By 60.72% .

What is Akebia Therapeutics Inc (AKBA) fair value?

How does AKBA's valuation metrics compare to the industry average?

What is the current P/B ratio for Akebia Therapeutics Inc (AKBA) as of Jul 27 2025?

What is the current FCF Yield for Akebia Therapeutics Inc (AKBA) as of Jul 27 2025?

What is the current Forward P/E ratio for Akebia Therapeutics Inc (AKBA) as of Jul 27 2025?
